Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study

Publisher： Karger

E-ISSN： 1423-0232|67|3-4|250-256

ISSN： 0030-2414

Source： Oncology, Vol.67, Iss.3-4, 2004-11, pp. : 250-256

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 438-445

Karger

Access to resources Recommend Favorite

Salvage Chemotherapy with Gemcitabine and Oxaliplatin in Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Phase II Study

By  

Oncology, Vol. 70, Iss. 4, 2006-10 ,pp. : 273-279

Karger

Access to resources Recommend Favorite

Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite

A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932

By  

Oncology, Vol. 69, Iss. 2, 2005-09 ,pp. : 117-121

Karger

Access to resources Recommend Favorite